- Home
- CVSA vs ERAS Comparison
CVSA vs ERAS Comparison
Compare CVSA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVSA | ERAS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 4996 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVSA | ERAS |
|---|---|---|
| Price | $118.50 | $19.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $150.00 | $14.25 |
| AVG Volume (30 Days) | 315.7K | ★ 5.6M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.66 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $96.08 | $1.33 |
| 52 Week High | $135.96 | $24.28 |
Technical Indicators
Market Signals| Indicator | CVSA | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 59.40 |
| Support Level | $115.79 | $12.36 |
| Resistance Level | $119.02 | $24.28 |
| Average True Range (ATR) | 5.94 | 1.41 |
| MACD | -1.50 | 0.01 |
| Stochastic Oscillator | 24.43 | 54.77 |
Price Performance
Historical ComparisonAbout CVSA Covista Inc. Common Shares
Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.